Premature Ejaculation

  • Chris G. McMahon
Part of the Springer Specialist Surgery Series book series (SPECIALIST)


Over the past 20–30 years, the PE treatment paradigm, previously limited to behavioral psychotherapy, has expanded to include drug treatment.1,2 Animal and human sexual psychopharmacological studies have demonstrated that serotonin and 5-HT receptors are involved in ejaculation and confirm a role for SSRIs in the treatment of PE.3-6 Multiple well-controlled evidence-based studies have demonstrated the efficacy and safety of SSRIs in delaying ejaculation, confirming their role as first-line agents for the treatment of lifelong and acquired PE.7 More recently, there has been increased attention to the psychosocial consequences of PE, its epidemiology, its etiology, and its pathophysiology by both clinicians and the pharmaceutical industry.8-13


Erectile Dysfunction Lower Urinary Tract Symptom Sexual Satisfaction Erectile Function Chronic Prostatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Semans JH. Premature ejaculation: a new approach. South Med J. 1956;49:353-358PubMedCrossRefGoogle Scholar
  2. 2.
    Masters WH, Johnson VE. Human Sexual Inadequacy. Boston, MA: Little Brown; 1970Google Scholar
  3. 3.
    Waldinger MD, Hengeveld M. Neuroseksuologie en seksuele psychofarmacologie. Tijdschr Psychiatr. 2000;8:585-593Google Scholar
  4. 4.
    Olivier B, van Oorschot R, Waldinger MD. Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol. 1998;13:S9-S14PubMedCrossRefGoogle Scholar
  5. 5.
    Waldinger MD, Rietschel M, Nothen MM, Hengeveld MW, Olivier B. Familial occurrence of primary premature ejaculation. Psychiatr Genet. 1998;8:37-40PubMedCrossRefGoogle Scholar
  6. 6.
    Pattij T, Olivier B, Waldinger MD. Animal models of ejaculatory behavior. Curr Pharm Des. 2005;11:4069-4077PubMedCrossRefGoogle Scholar
  7. 7.
    Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004;16:369-381PubMedCrossRefGoogle Scholar
  8. 8.
    Metz ME, Pryor JL, Nesvacil LJ, Abuzzahab F Sr, Koznar J. Premature ejaculation: a psychophysiological review. J Sex Marital Ther. 1997;23:3-23PubMedGoogle Scholar
  9. 9.
    Symonds T, Roblin D, Hart K, Althof S. How does premature ejaculation impact a man’s life? J Sex Marital Ther. 2003;29:361-370PubMedCrossRefGoogle Scholar
  10. 10.
    Waldinger MD, Quinn P, Dilleen M, Mundayat R, Schweitzer DH, Boolell M. A multinational population survey of intravaginal ejaculation latency time. J Sex Med. 2005;2:492-497PubMedCrossRefGoogle Scholar
  11. 11.
    Patrick DL, Althof SE, Pryor JL, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005;2:58-367CrossRefGoogle Scholar
  12. 12.
    Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007;51:816-823PubMedCrossRefGoogle Scholar
  13. 13.
    Giuliano F, Patrick DL, Porst H, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008;53:1048-1057PubMedCrossRefGoogle Scholar
  14. 14.
    Reading A, Wiest W. An analysis of self-reported sexual behavior in a sample of normal males. Arch Sex Behav. 1984;13:69-83PubMedCrossRefGoogle Scholar
  15. 15.
    Nathan SG. The epidemiology of the DSM-III psychosexual dysfunctions. J Sex Marital Ther. 1986;12:267-281PubMedGoogle Scholar
  16. 16.
    Spector KR, Boyle M. The prevalence and perceived aetiology of male sexual problems in a non-clinical sample. Br J Med Psychol. 1986;59:351-358PubMedGoogle Scholar
  17. 17.
    Spector IP, Carey M. Incidence and prevalence of the sexual dysfunctions: a critical review of the empirical literature. Arch Sex Behav. 1990;19:389PubMedCrossRefGoogle Scholar
  18. 18.
    Grenier G, Byers ES. The relationships among ejaculatory control, ejaculatory latency, and attempts to prolong heterosexual intercourse. Arch Sex Behav. 1997;26:27-47PubMedCrossRefGoogle Scholar
  19. 19.
    Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. J Am Med Assoc. 1999;281:537-544CrossRefGoogle Scholar
  20. 20.
    Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Proposal for a definition of lifelong premature ejaculation based on epidemiological stopwatch data. J Sex Med. 2005;2:498-507PubMedCrossRefGoogle Scholar
  21. 21.
    Schapiro B. Premature ejaculation, a review of 1,130 cases. J Urol. 1943;50:374-379Google Scholar
  22. 22.
    Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs. 2007;67:547-568PubMedCrossRefGoogle Scholar
  23. 23.
    Hartmann U, Schedlowski M, Kruger TH. Cognitive and partner-related factors in rapid ejaculation: differences between dysfunctional and functional men. World J Urol. 2005;10:10Google Scholar
  24. 24.
    Laumann EO, Nicolosi A, Glasser DB, et al. Sexual problems among women and men aged 40–80 years: prevalence and correlates identified in the global study of sexual attitudes and behaviors. Int J Impot Res. 2005;17:39-57PubMedCrossRefGoogle Scholar
  25. 25.
    Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Prevalence of chronic prostatitis in men with premature ejaculation. Urology. 2001;58:198-202PubMedCrossRefGoogle Scholar
  26. 26.
    Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab. 2005;90:6472-6479PubMedCrossRefGoogle Scholar
  27. 27.
    Adson DE, Kotlyar M. Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother. 2003;37:1804-1806PubMedCrossRefGoogle Scholar
  28. 28.
    Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001;33:223-232PubMedGoogle Scholar
  29. 29.
    McMahon CG. Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int J Impot Res. 2002;14:S19CrossRefGoogle Scholar
  30. 30.
    Waldinger MD, Schweitzer DH. Changing paradigms from a historical DSM-III and DSM-IV view toward an evidence-based definition of premature ejaculation. Part II-proposals for DSM-V and ICD-11. J Sex Med. 2006;3:693-705PubMedCrossRefGoogle Scholar
  31. 31.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994Google Scholar
  32. 32.
    World Health Organization. International Classification of Diseases and Related Health Problems. 10th ed. Geneva: World Health Organization; 1994Google Scholar
  33. 33.
    Metz M, McCarthy B. Coping with Premature Ejaculation: How to Overcome PE, Please Your Partner and Have Great Sex. Oakland: New Harbinber Publications; 2003Google Scholar
  34. 34.
    Montague DK, Jarow J, Broderick GA, et al. AUA guideline on the pharmacologic management of premature ejaculation. J Urol. 2004;172:290-294PubMedCrossRefGoogle Scholar
  35. 35.
    Colpi G, Weidner W, Jungwirth A, et al. EAU guidelines on ejaculatory dysfunction. Eur Urol. 2004;46:555-558PubMedCrossRefGoogle Scholar
  36. 36.
    McMahon CG, Abdo C, Incrocci I, et al. Disorders of orgasm and ejaculation in men. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F, eds. Sexual Medicine: Sexual Dysfunctions in Men and Women (2nd International Consultation on Sexual Dysfunctions-Paris). Paris: France Health Publications; 2004:409-468Google Scholar
  37. 37.
    Jannini EA, Lombardo F, Lenzi A. Correlation between ejaculatory and erectile dysfunction. Int J Androl. 2005;28(Suppl 2):40-45PubMedCrossRefGoogle Scholar
  38. 38.
    Centre for Evidence-based Medicine. Oxford Centre for Evidence-based Medicine Levels of Evidence; May 2001. Accessed February 8, 2008 [cited]
  39. 39.
    Althof SE, Symonds T. Patient reported outcomes used in the assessment of premature ejaculation. Urol Clin North Am. 2007;34:581-589PubMedCrossRefGoogle Scholar
  40. 40.
    McMahon CG, Althof SE, Waldinger MD, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med. 2008;5:1590-1606PubMedCrossRefGoogle Scholar
  41. 41.
    Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double blind, randomized, placebo controlled study. Am J Psychiatry. 1994;151:1377-1379PubMedGoogle Scholar
  42. 42.
    Spiess WF, Geer JH, O’Donohue WT. Premature ejaculation: investigation of factors in ejaculatory latency. J Abnorm Psychol. 1984;93:242-245PubMedCrossRefGoogle Scholar
  43. 43.
    Strassberg DS, Kelly MP, Carroll C, Kircher JC. The psychophysiological nature of premature ejaculation. Arch Sex Behav. 1987;16:327-336PubMedCrossRefGoogle Scholar
  44. 44.
    Kilmann PR, Auerbach R. Treatments of premature ejaculation and psychogenic impotence: a critical review of the literature. Arch Sex Behav. 1979;8:81-100PubMedCrossRefGoogle Scholar
  45. 45.
    Schover L, Friedman J, Weiler S, Heiman J, LoPiccolo J. Multiaxial problem-oriented system for sexual dysfunctions. Arch Gen Psychiatry. 1982;39:614-619PubMedGoogle Scholar
  46. 46.
    Waldinger M, Hengeveld M, Zwinderman A, Olivier B. An empirical operationalization of DSM-IV diagnostic criteria for premature ejaculation. Int J Psychiatr Clin Pract. 1998;2:287-293CrossRefGoogle Scholar
  47. 47.
    Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med. 2007;4:1028-1037PubMedCrossRefGoogle Scholar
  48. 48.
    Althof SE, Levine SB, Corty EW, Risen CB, Stern EB, Kurit DM. A double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry. 1995;56:402-407PubMedGoogle Scholar
  49. 49.
    Pryor JL, Broderick GA, Ho KF, Jamieson C, Gagnon D. Comparison of estimated versus measured intravaginal ejaculatory latency time (IELT) in Men with and without premature ejaculation (PE). J Sex Med. 2005;3:54 (Abstract 126)Google Scholar
  50. 50.
    Rosen RC, McMahon CG, Niederberger C, Broderick GA, Jamieson C, Gagnon DD. Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. J Urol. 2007;177:1059-1064; discussion 64PubMedCrossRefGoogle Scholar
  51. 51.
    Kaplan HS, Kohl RN, Pomeroy WB, Offit AK, Hogan B. Group treatment of premature ejaculation. Arch Sex Behav. 1974;3:443-452PubMedCrossRefGoogle Scholar
  52. 52.
    McCarthy B. Cognitive-behavioural strategies and techniques in the treatment of early ejaculation. In: Leiblum SR, Rosen R, eds. Principles and Practices of Sex Therapy: Update for the 1990s. New York: Guilford; 1988:141-167Google Scholar
  53. 53.
    Vandereycken W. Towards a better delineation of ejaculatory disorders. Acta Psychiatr Belg. 1986;86:57-63PubMedGoogle Scholar
  54. 54.
    Zilbergeld B. Male Sexuality. Toronto: Bantam; 1978Google Scholar
  55. 55.
    Grenier G, Byers S. Operationalizing premature or rapid ejaculation. J Sex Res. 2001;38:369-378CrossRefGoogle Scholar
  56. 56.
    Rowland DL, Strassberg DS, de Gouveia Brazao CA, Slob AK. Ejaculatory latency and control in men with premature ejaculation: an analysis across sexual activities using multiple sources of information. J Psychosom Res. 2000;48:69-77PubMedCrossRefGoogle Scholar
  57. 57.
    Giuliano F, Patrick DL, Porst H, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. October 16, 2007 [Epub ahead of print]Google Scholar
  58. 58.
    Rowland D, Perelman M, Althof S, et al. Self-reported premature ejaculation and aspects of sexual functioning and satisfaction. J Sex Med. 2004;1:225-232PubMedCrossRefGoogle Scholar
  59. 59.
    Dunn KM, Croft PR, Hackett GI. Association of sexual problems with social, psychological, and physical problems in men and women: a cross sectional population survey. J Epidemiol Community Health. 1999;53:144-148PubMedCrossRefGoogle Scholar
  60. 60.
    Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. J Urol. 2007;177:1065-1070PubMedCrossRefGoogle Scholar
  61. 61.
    Rosen R, Althof S. Psychological consequences of PE, quality of life and impact on sexual relationships. J Sex Med. 2008;5:1296-1307PubMedCrossRefGoogle Scholar
  62. 62.
    McCabe MP. Intimacy and quality of life among sexually dysfunctional men and women. J Sex Marital Ther. 1997;23:276-290PubMedGoogle Scholar
  63. 63.
    Byers ES, Grenier G. Premature or rapid ejaculation: heterosexual couples’ perceptions of men’s ejaculatory behavior. Arch Sex Behav. 2003;32:261-270PubMedCrossRefGoogle Scholar
  64. 64.
    Riley A, Riley E. Premature ejaculation: presentation and associations. An audit of patients attending a sexual problems clinic. Int J Clin Pract. 2005;59:1482-1487PubMedCrossRefGoogle Scholar
  65. 65.
    Brock GB, Gajewski J, Carrier S, Bernard F, Lee J, Pommerville PJ. The prevalence and impact of premature ejaculation in Canada. Proceedings of Annual Meeting of the American Urological Association; May 19-24, 2007; Anaheim, CAGoogle Scholar
  66. 66.
    Althof SE. Prevalence, characteristics and implications of premature ejaculation/rapid ejaculation. J Urol. 2006;175:842-848PubMedCrossRefGoogle Scholar
  67. 67.
    Althof S. The psychology of premature ejaculation: therapies and consequences. J Sex Med. 2006;3(Suppl 4):324-331PubMedCrossRefGoogle Scholar
  68. 68.
    Jern P, Santtila P, Witting K, et al. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med. 2007;4:1739-1749PubMedCrossRefGoogle Scholar
  69. 69.
    Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res. 1998;92:111-118PubMedCrossRefGoogle Scholar
  70. 70.
    Waldinger MD. The neurobiological approach to premature ejaculation. J Urol. 2002;168:2359-2367PubMedCrossRefGoogle Scholar
  71. 71.
    Janssen PKC, Bakker SC, Réthelyi J, et al. Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ejaculation latency time in Dutch men with lifelong premature ejaculation. J Sex Med. 2008;6:276-284CrossRefGoogle Scholar
  72. 72.
    de Carufel F, Trudel G. Effects of a new functional-sexological treatment for premature ejaculation. J Sex Marital Ther. 2006;32:97-114PubMedCrossRefGoogle Scholar
  73. 73.
    De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Clinical follow-up of couples treated for sexual dysfunction. Arch Sex Behav. 1985;14:467-489PubMedCrossRefGoogle Scholar
  74. 74.
    Hawton K, Catalan J, Martin P, Fagg J. Long-term outcome of sex therapy. Behav Res Ther. 1986;24:665-675PubMedCrossRefGoogle Scholar
  75. 75.
    Perelman MA. A new combination treatment for premature ejaculation: a sex therapist’s perspective. J Sex Med. 2006;3:1004-1012PubMedCrossRefGoogle Scholar
  76. 76.
    Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. Br Med J. 2004;328(7454):1490CrossRefGoogle Scholar
  77. 77.
    Waldinger M. Towards evidenced based drug treatment research on premature ejaculation: a critical evaluation of methodology. J Impot Res. 2003;15:309-313CrossRefGoogle Scholar
  78. 78.
    Atmaca M, Kuloglu M, Tezcan E, Semercioz A. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14:502-505PubMedCrossRefGoogle Scholar
  79. 79.
    McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol. 1998;159:1935-1938PubMedCrossRefGoogle Scholar
  80. 80.
    Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996;156:1631-1632PubMedCrossRefGoogle Scholar
  81. 81.
    Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994;151:1377-1379PubMedGoogle Scholar
  82. 82.
    Goodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res. 1980;8:53-59PubMedGoogle Scholar
  83. 83.
    Waldinger MD. Drug treatment of premature ejaculation: pharmacodynamic and pharmacokinetic paradigms. Drug Discov Today Ther Strateg. 2005;2:37-40CrossRefGoogle Scholar
  84. 84.
    Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. J Clin Psychiatry. 2008;69:916-922PubMedCrossRefGoogle Scholar
  85. 85.
    Mann JJ, Emslie G, Baldessarini RJ, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology. 2006;31:473-492PubMedCrossRefGoogle Scholar
  86. 86.
    Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790-792PubMedCrossRefGoogle Scholar
  87. 87.
    Ditto KE. SSRI discontinuation syndrome. Awareness as an approach to prevention. Postgrad Med. 2003;114:79-84PubMedCrossRefGoogle Scholar
  88. 88.
    Black K, Shea CA, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255-261PubMedGoogle Scholar
  89. 89.
    Li N, Wallen NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis. 1997;8:517-523PubMedCrossRefGoogle Scholar
  90. 90.
    Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf. 2005;4:337-344PubMedCrossRefGoogle Scholar
  91. 91.
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343:769-772PubMedCrossRefGoogle Scholar
  92. 92.
    Ahmad S. Paroxetine-induced priapism. Arch Intern Med. 1995;155:645PubMedCrossRefGoogle Scholar
  93. 93.
    Rand EH. Priapism in a patient taking sertraline. J Clin Psychiatry. 1998;59:538PubMedCrossRefGoogle Scholar
  94. 94.
    Dent LA, Brown WC, Murney JD. Citalopram-induced priapism. Pharmacotherapy. 2002;22:538-541PubMedCrossRefGoogle Scholar
  95. 95.
    Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863-867PubMedCrossRefGoogle Scholar
  96. 96.
    Cavallini G. Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. Eur Urol. 1995;28:126-130PubMedGoogle Scholar
  97. 97.
    Basar MM, Yilmaz E, Ferhat M, Basar H, Batislam E. Terazosin in the treatment of premature ejaculation: a short-term follow-up. Int Urol Nephrol. 2005;37:773-777PubMedCrossRefGoogle Scholar
  98. 98.
    McMahon CG, Touma K. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol. 1999;161:1826-1830PubMedCrossRefGoogle Scholar
  99. 99.
    Strassberg DS, de Gouveia Brazao CA, Rowland DL, Tan P, Slob AK. Clomipramine in the treatment of rapid (premature) ejaculation. J Sex Marital Ther. 1999;25:89-101PubMedCrossRefGoogle Scholar
  100. 100.
    Kim SW, Paick JS. Short-term analysis of the effects of as needed use of sertraline at 5 PM for the treatment of premature ejaculation. Urology. 1999;54:544-547PubMedCrossRefGoogle Scholar
  101. 101.
    Waldinger MD, Zwinderman AH, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment. Eur Urol. 2004;46:510-515PubMedGoogle Scholar
  102. 102.
    Dresser MJ, Lindert K, Lin D. Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clin Pharmacol Ther. 2004;75:113 (Abstract P1)Google Scholar
  103. 103.
    Dresser M, Modi NB, Staehr P, Mulhall JP. The effect of food on the pharmacokinetics of dapoxetine, a new on-demand treatment for premature ejaculation. J Sex Med. 2005;3:25 (Abstract 37)Google Scholar
  104. 104.
    Modi NB, Dresser M, Desai D. Dapoxetine, a new on-demand treatment for premature ejaculation exhibits rapid single and multiple-dose pharmacokinetics. J Sex Med. 2006;3:228 (Abstract P-02-162)Google Scholar
  105. 105.
    Modi NB, Dresser M, Desai D, Edgar C, Wesnes K. Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007;47:315-322PubMedCrossRefGoogle Scholar
  106. 106.
    Dresser MJ, Desai D, Gidwani S, Seftel AD, Modi NB. Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors. Int J Impot Res. 2006;18:104-110PubMedCrossRefGoogle Scholar
  107. 107.
    Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006;368:929-937PubMedCrossRefGoogle Scholar
  108. 108.
    Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998;18:274-281PubMedCrossRefGoogle Scholar
  109. 109.
    Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Geometric mean IELT and premature ejaculation: appropriate statistics to avoid overestimation of treatment efficacy. J Sex Med. 2008;5:492-499PubMedCrossRefGoogle Scholar
  110. 110.
    McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies—Part II—Study design, outcome measures, data analysis, and reporting. J Sex Med. 2008;5:1817-1833PubMedCrossRefGoogle Scholar
  111. 111.
    Levine SB, Casey RW, Ramagopal VM, Hashmonay R. Evaluation of withdrawal effects with dapoxetine in the treatment of premature ejaculation (PE). J Sex Medicine, Jan 2007;4(Supp 1), 91Google Scholar
  112. 112.
    Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung. 1996;46:1029-1036PubMedGoogle Scholar
  113. 113.
    Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006;26:27-31PubMedCrossRefGoogle Scholar
  114. 114.
    Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2007;5:188-193PubMedGoogle Scholar
  115. 115.
    Cossmann M, Kohnen C, Langford R, McCartney C. Tolerance and safety of tramadol use. Results of international studies and data from drug surveillance. Drugs. 1997;53:50-62PubMedCrossRefGoogle Scholar
  116. 116.
    McDiarmid T, Mackler L, Schneider DM. Clinical inquiries. What is the addiction risk associated with tramadol? J Fam Pract. 2005;54:72-73PubMedGoogle Scholar
  117. 117.
    Adams EH, Breiner S, Cicero TJ, et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage. 2006;31:465-476PubMedCrossRefGoogle Scholar
  118. 118.
    Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol. 1995;154:1360-1361PubMedCrossRefGoogle Scholar
  119. 119.
    Xin ZC, Choi YD, Lee SH, Choi HK. Efficacy of a topical agent SS-cream in the treatment of premature ejaculation: preliminary clinical studies. Yonsei Med J. 1997;38:91-95PubMedGoogle Scholar
  120. 120.
    Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004;93:1018-1021PubMedCrossRefGoogle Scholar
  121. 121.
    Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int. 2006;99:369-375PubMedCrossRefGoogle Scholar
  122. 122.
    Henry R, Morales A, Wyllie MG. TEMPE: topical eutectic-like mixture for premature ejaculation. Expert Opin Drug Deliv. 2008;5:251-261PubMedCrossRefGoogle Scholar
  123. 123.
    Fein RL. Intracavernous medication for treatment of premature ejaculation. Urology. 1990;35:301-303PubMedCrossRefGoogle Scholar
  124. 124.
    Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res. 2001;13:41-45PubMedCrossRefGoogle Scholar
  125. 125.
    Salonia A, Maga T, Colombo R, et al. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. J Urol. 2002;168:2486-2489PubMedCrossRefGoogle Scholar
  126. 126.
    Zhang XS, Wang YX, Huang XY, Leng J, Li Z, Han YF. Comparison between sildenafil plus sertraline and sertraline alone in the treatment of premature ejaculation. Zhonghua Nan Ke Xue. 2005;11:520-522, 525Google Scholar
  127. 127.
    Chen J, Mabjeesh NJ, Matzkin H, Greenstein A. Efficacy of sildenafil as adjuvant therapy to selective serotonin reuptake inhibitor in alleviating premature ejaculation. Urology. 2003;61:197-200PubMedCrossRefGoogle Scholar
  128. 128.
    Tang W, Ma L, Zhao L, Liu Y, Chen Z. Clinical efficacy of Viagra with behavior therapy against premature ejaculation. Zhonghua Nan Ke Xue. 2004;10:366-367, 370Google Scholar
  129. 129.
    McMahon CG, Stuckey B, Andersen ML. Efficacy of Viagra:Sildenafil Citrate in men with premature ejaculation. J Sex Med. 2005;2:368-375PubMedCrossRefGoogle Scholar
  130. 130.
    Li X, Zhang SX, Cheng HM, Zhang WD. Clinical study of sildenafil in the treatment of premature ejaculation complicated by erectile dysfunction. Zhonghua Nan Ke Xue. 2003;9:266-269PubMedGoogle Scholar
  131. 131.
    Lozano AF. Premature ejaculation. Pharmacological treatment. Three years after. Int J Impot Res. 2003;15:S11 (Abstract MP-2-6)CrossRefGoogle Scholar
  132. 132.
    Sommer F, Klotz T, Mathers MJ. Treatment of premature ejaculation: a comparative vardenafil and SSRI crossover study. J Urol. 2005;173:202 (Abstract 741)CrossRefGoogle Scholar
  133. 133.
    Mattos RM, Lucon AM. Tadalafil and slow-release fluoxetine in premature ejaculation - a prospective study. J Urol. 2005;173:239 (Abstract 880)CrossRefGoogle Scholar
  134. 134.
    Erenpreiss J, Zalkalns J. Premature ejaculation: comparison of patroxetine alone, paroxetine plus local lidocaine and paroxetine plus sildenafil. Int J Impot Res. 2002;14:S33 (Abstract PS-7-4)Google Scholar
  135. 135.
    Linn R, Ginesin Y, Hardak S, Mertyk S. Treatment of sildenfil as part of the treatment in premature ejaculation. Int J Impot Res. 2002;14:S39 (Abstract P-168)CrossRefGoogle Scholar
  136. 136.
    Chia S. Management of premature ejaculation – a comparison of treatment outcome in patients with and without erectile dysfunction. Int J Androl. 2002;25:301-305PubMedCrossRefGoogle Scholar
  137. 137.
    Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in treatment of premature ejaculation. Urology. 2006;67:388-391PubMedCrossRefGoogle Scholar
  138. 138.
    Mamas MA, Reynard JM, Brading AF. Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology. 2003;61:1079-1085PubMedCrossRefGoogle Scholar
  139. 139.
    McMahon CG, McMahon CN, Leow LJ, Winestock CG. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int. 2006;98:259-272PubMedCrossRefGoogle Scholar
  140. 140.
    McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies – Part I – Defining and selecting the study population. J Sex Med. 2008;5:1805-1816PubMedCrossRefGoogle Scholar
  141. 141.
    McMahon CG. Clinical trial methodology in premature ejaculation observational, interventional, and treatment preference studies – Part II–Study design, outcome measures, data analysis, and reporting. J Sex Med. 2008;5:1817-1833PubMedCrossRefGoogle Scholar
  142. 142.
    Corona G, Petrone L, Mannucci E, et al. Psycho-biological correlates of rapid ejaculation in patients attending an andrologic unit for sexual dysfunctions. Eur Urol. 2004;46:615-622PubMedCrossRefGoogle Scholar
  143. 143.
    Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori AM, Fabbri A. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod. 2000;15:131-134PubMedCrossRefGoogle Scholar
  144. 144.
    Mondaini N, Ponchietti R, Muir GH, et al. Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. Int J Impot Res. 2003;15:225-228PubMedCrossRefGoogle Scholar
  145. 145.
    Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol. 1998;138:1-9PubMedCrossRefGoogle Scholar
  146. 146.
    Musselman DL, Nemeroff CB. Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psychiatry, Jun 1996;30:123-128PubMedGoogle Scholar
  147. 147.
    Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry. 1990;47:435-440PubMedGoogle Scholar
  148. 148.
    Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry. 2002;7:140-156PubMedCrossRefGoogle Scholar
  149. 149.
    Bauer M, London ED, Silverman DH, Rasgon N, Kirchheiner J, Whybrow PC. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003;36(Suppl 3):S215-S221PubMedGoogle Scholar
  150. 150.
    Gitlin M, Altshuler LL, Frye MA, et al. Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors. J Psychiatry Neurosci. 2004;29:383-386PubMedGoogle Scholar
  151. 151.
    Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res. 1993;614:37-44PubMedCrossRefGoogle Scholar
  152. 152.
    Eison AS, Mullins UL. Regulation of central 5-HT2A receptors: a review of in vivo studies. Behav Brain Res. 1996;73:177-181PubMedCrossRefGoogle Scholar
  153. 153.
    Kulikov AV, Maksyutova AV, Ivanova EA, Khvorostov IB, Popova NK. The effect of thyroidectomy on the expression of the mRNA of 5-HT2A serotonin receptors in the rat frontal cortex. Dokl Biochem Biophys. 2002;383:116-118PubMedCrossRefGoogle Scholar
  154. 154.
    Kulikov AV, Zubkov EA. Chronic thyroxine treatment activates the 5-HT2A serotonin receptor in the mouse brain. Neurosci Lett. 2007;416:307-309PubMedCrossRefGoogle Scholar
  155. 155.
    Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. Thyroid-stimulating hormone assessments in a Dutch cohort of 620 men with lifelong premature ejaculation without erectile dysfunction. J Sex Med. 2005;2:865-870PubMedCrossRefGoogle Scholar
  156. 156.
    Atkinson RL, Dahms WT, Fisher DA, Nichols AL. Occult thyroid disease in an elderly hospitalized population. J Gerontol. 1978;33:372-376PubMedGoogle Scholar
  157. 157.
    Nickel JC, Elhilali M, Vallancien G. Benign prostatic hyperplasia (BPH) and prostatitis: prevalence of painful ejaculation in men with clinical BPH. BJU Int. 2005;95:571-574PubMedCrossRefGoogle Scholar
  158. 158.
    Qiu YC, Xie CY, Zeng XD, Zhang JH. Investigation of sexual function in 623 patients with chronic prostatitis. Zhonghua Nan Ke Xue. 2007;13:524-526PubMedGoogle Scholar
  159. 159.
    Gonen M, Kalkan M, Cenker A, Ozkardes H. Prevalence of premature ejaculation in Turkish men with chronic pelvic pain syndrome. J Androl. 2005;26:601-603PubMedCrossRefGoogle Scholar
  160. 160.
    Beutel ME, Weidner W, Brahler E. Chronic pelvic pain and its comorbidity. Urologe A. 2004;43:261-267PubMedCrossRefGoogle Scholar
  161. 161.
    Liang CZ, Zhang XJ, Hao ZY, Shi HQ, Wang KX. Prevalence of sexual dysfunction in Chinese men with chronic prostatitis. BJU Int. 2004;93:568-570PubMedCrossRefGoogle Scholar
  162. 162.
    Trinchieri A, Magri V, Cariani L, et al. Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome. Arch Ital Urol Androl. 2007;79:67-70PubMedGoogle Scholar
  163. 163.
    Xing JP, Fan JH, Wang MZ, Chen XF, Yang ZS. Survey of the prevalence of chronic prostatitis in men with premature ejaculation. Zhonghua Nan Ke Xue. 2003;9:451-453PubMedGoogle Scholar
  164. 164.
    Shamloul R, el-Nashaar A. Chronic prostatitis in premature ejaculation: a cohort study in 153 men. J Sex Med. 2006;3:150-154PubMedCrossRefGoogle Scholar
  165. 165.
    Boneff AN. Topical treatment of chronic prostatitis and premature ejaculation. Int Urol Nephrol. 1972;4:183-186PubMedCrossRefGoogle Scholar
  166. 166.
    Brown AJ. Ciprofloxacin as cure of premature ejaculation. J Sex Marital Ther. 2000;26:351-352PubMedCrossRefGoogle Scholar
  167. 167.
    El-Nashaar A, Shamloul R. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med. 2007;4:491-496PubMedCrossRefGoogle Scholar
  168. 168.
    Cremers TI, De Boer P, Liao Y, et al. Augmentation with a 5-HT1A, but not a 5-HT1B receptor antagonist critically depends on the dose of citalopram. Eur J Pharmacol. 2000;397:63-74PubMedCrossRefGoogle Scholar
  169. 169.
    Williamson IJ, Turner L, Woods K, Wayman CP, van der Graaf PH. The 5-HT1A receptor antagonist robalzotan enhances SSRI-induced ejaculation delay in the rat. Br J Pharmacol Biochem Behav. 2003;138:PO32Google Scholar
  170. 170.
    de Jong TR, Pattij T, Veening JG, et al. Citalopram combined with WAY 100635 inhibits ejaculation and ejaculation-related Fos immunoreactivity. Eur J Pharmacol. 2005;509:49-59 [Epub January 21, 2005]PubMedCrossRefGoogle Scholar
  171. 171.
    Safarinejad MR. Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. J Clin Psychopharmacol. 2008;28:39-44PubMedCrossRefGoogle Scholar
  172. 172.
    Carmichael MS, Humbert R, Dixen J, Palmisano G, Greenleaf W, Davidson JM. Plasma oxytocin increases in the human sexual response. J Clin Endocrinol Metab. 1987;64:27-31PubMedCrossRefGoogle Scholar
  173. 173.
    Uckert S, Becker AJ, Ness BO, et al. Oxytocin plasma levels in the systemic and cavernous blood of healthy males during different penile conditions. World J Urol. 2003;20:323-326PubMedGoogle Scholar
  174. 174.
    Honda K, Yanagimoto M, Negoro H, Narita K, Murata T, Higuchi T. Excitation of oxytocin cells in the hypothalamic supraoptic nucleus by electrical stimulation of the dorsal penile nerve and tactile stimulation of the penis in the rat. Brain Res Bull. 1999;48:309-313PubMedCrossRefGoogle Scholar
  175. 175.
    Yanagimoto M, Honda K, Goto Y, Negoro H. Afferents originating from the dorsal penile nerve excite oxytocin cells in the hypothalamic paraventricular nucleus of the rat. Brain Res. 1996;733:292-296PubMedCrossRefGoogle Scholar
  176. 176.
    Arletti R, Bazzani C, Castelli M, Bertolini A. Oxytocin improves male copulatory performance in rats. Horm Behav. 1985;19:14-20PubMedCrossRefGoogle Scholar
  177. 177.
    Arletti R, Benelli A, Bertolini A. Sexual behavior of aging male rats is stimulated by oxytocin. Eur J Pharmacol. 1990;179:377-381PubMedCrossRefGoogle Scholar
  178. 178.
    Gupta J, Russell RJ, Wayman CP, Hurley D, Jackson VM. Oxytocin-induced contractions within rat and rabbit ejaculatory tissues are mediated by vasopressin V(1A) receptors and not oxytocin receptors. Br J Pharmacol. 2008;55:118-126CrossRefGoogle Scholar
  179. 179.
    Kim JJ, Kwak TI, Jeon BG, Cheon J, Moon DG. Effects of glans penis augmentation using hyaluronic acid gel for premature ejaculation. Int J Impot Res. 2004;16:547-551PubMedCrossRefGoogle Scholar
  180. 180.
    Shi WG, Wang XJ, Liang XQ, et al. Selective resection of the branches of the two dorsal penile nerves for primary premature ejaculation. Zhonghua Nan Ke Xue. 2008;14:436-438PubMedGoogle Scholar
  181. 181.
    Kwak TI, Jin MH, Kim JJ, Moon DG. Long-term effects of glans penis augmentation using injectable hyaluronic acid gel for premature ejaculation. Int J Impot Res. 2008;20:425-428PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Chris G. McMahon
    • 1
  1. 1.Australian Centre for Sexual Health, Suite 2–4, Berry Road Medical CentreUniversity of SydneySt LeonardsAustralia

Personalised recommendations